DOCSLIB.ORG

The Sabin Story 06 Why We Fight Diseases of Poverty 08 2010 in Review 11 Measuring Success

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Sabin Story 06 Why We Fight Diseases of Poverty 08 2010 in Review 11 Measuring Success SABIN VACCINE INSTITUTE Partnering for a Healthier World 1 TABLE OF CONTENTS 02 Letter from the Chairman and CEO 03 Message from the President 05 The Sabin Story 06 Why We Fight Diseases of Poverty 08 2010 in Review 11 Measuring Success Program Updates 12 Vaccine Advocacy and Education 16 Vaccine Development 20 Global Network for Neglected Tropical Diseases Profiles 24 Profile 1: NTD Vaccine Development 26 Profile 2: Ending the Neglect in Burundi 28 Profile 3: Immunization Financing in Cambodia 30 Our Partners 32 Board of Trustees and Staff 34 Financials 36 Sabin Scholar Awards and Appointments 37 In Memoriam TO REDUCE NEEDLESS HUMAN SUFFERING FROM vaccine- PReventabLE AND NEGLECTED TROPicaL DISEASES BY DEVELOPING NEW vaccines, ADVOcatinG FOR INCREASED USE OF EXISTING vaccines, AND PROMOTING EXPANDED ACCESS TO AFFORDABLE MEDicaL TReatMENTS. 2 Sabin Annual Report 2010 1 from the from the LETTER Chairman and CEO MESSAGE President Dear Sabin Supporters: Sabin’s Vaccine Advocacy and Education initiative Dear Friends: Relocating the vaccine program to TMC will allow advances policies that improve access to vaccines our team of a dozen scientists and support staff to We are pleased to present the Albert B. Sabin Vaccine which prevent transmission of a multitude of As you will read in the pages that follow, 2010 was embark on new collaborations for vaccine discovery, Institute’s 2010 Annual Report and to share with infectious diseases. Spurred on by our Sustainable particularly notable for our efforts to control and delivery, and testing, at a world-class institution you our most significant developments since our last Immunization Financing program, seven of 15 ultimately eliminate neglected tropical diseases, the in a major gateway city to Latin America. Both the letter. As this report makes clear, the breadth and target countries increased their immunization budgets most common afflictions of the world’s poorest hookworm and schistosomiasis vaccines will undergo scope of Sabin’s three principal programs have grown and nine countries began writing new immunization billion people. clinical development and ultimately industrial significantly as we continue to play a leadership financing legislation. The Coalition against scale manufacture in Brazil, and we plan to develop role in the global fight against vaccine-preventable Typhoid, a new program launched in 2010, quickly In the area of research and development, our vaccine a Chagas disease vaccine in Mexico. and neglected tropical diseases (NTDs). became a major resource for countries seeking to development program and PDP—the Sabin Vaccine develop implementation policies and secure funding Institute Product Development Partnership—advanced In the area of policy and delivery, our Global Network While progress continues to be made in bringing new for World Health Organization (WHO) prequalified three new “anti-poverty vaccines” to combat NTDs. for Neglected Tropical Diseases, under the direction vaccines and treatments to the market, there remains typhoid vaccines. The two antigen components of our human hook- of Dr. Neeraj Mistry, continues to make great progress a large gap in getting life-saving interventions to worm vaccine were successfully manufactured and in elevating the profile of these conditions, and we the world’s poorest people. Millions of children still Another core initiative, the Global Network for we submitted regulatory filings in the U.S. and look forward to revealing some innovative approaches die each year because they are not being vaccinated. Neglected Tropical Diseases, expanded its advocacy Brazil prior to anticipated clinical testing in Brazil. to “get the word out” about these conditions in the Nearly 1.4 billion people remain trapped in poverty, and resource mobilization for integrated NTD treatment Our schistosomiasis vaccine will also soon be manu- coming months. At the same time, Dr. Ciro de Quadros in part because they do not have access to medicines programs, also known as mass drug administrations factured and we launched efforts to make a new leads an incredibly effective effort to expand global —many of which are donated by pharmaceutical or MDAs. Through MDAs, for approximately $0.50 per Chagas disease vaccine. We continue to be deeply access of all major childhood vaccines as well as firms—that offer effective treatment against the seven person, we can treat and prevent up to seven grateful to the Bill & Melinda Gates Foundation and to ensure that the “decade of vaccines” meets its most prevalent NTDs. To avoid drug resistance NTDs for a year. Working with a range of international the Brazilian Ministry of Health for their unwavering ambitious targets. problems in the future and provide definitive, long- partners, we developed regional funds that will support of the hookworm vaccine, now joined with term solutions, vaccines for some of these diseases efficiently channel donations to NTD control programs a major co-investment from the Dutch Ministry of With the move of the Sabin vaccine development labs must be developed. Sabin exists to bridge these gaps in Africa, Latin America, and the Caribbean. Foreign Affairs. For the schistosomiasis vaccine, the to Houston, I will also become the founding Dean of by providing poor and underserved communities ongoing support of the Blavatnik Family Foundation, a new National School of Tropical Medicine, the first around the world with better access to vital medical To further these initiatives and programs, we formed and Mort and Chris Hyman, and now the National of its kind in the United States, at Baylor College of treatments and vaccines. an affiliate in the United Kingdom, Sabin Foundation Institute of Allergy and Infectious Diseases of the U.S. Medicine. I invite you to come and visit our labs in Europe. Its leaders will focus on expanding awareness National Institutes of Health, has been absolutely Houston, Texas and enjoy one of the most culturally Sabin continues to pioneer the development of and support of the Sabin mission throughout Europe. critical. We are equally grateful for the new support of vibrant and international cities in the U.S.! low-cost vaccines to prevent human hookworm, the PDP by the Carlos Slim Health Institute in Mexico schistosomiasis, and other diseases. Our unique Sabin plays a unique and vital role in providing to begin efforts for a new therapeutic vaccine for Warmest regards, vaccine product development partnership (PDP), which solutions to the health burdens of the world’s poor Chagas disease and related infections. involves collaborators from across the globe, including and we will remain at the forefront of the fight against Brazil, Australia, and China, recently grew in stature diseases of poverty. We truly appreciate your Our expansion into additional vaccines beyond and scope through a new affiliation with Baylor College generous contributions, which are the foundation of hookworm and schistosomiasis coincides with the of Medicine (BCM) and Texas Children’s Hospital our success, and look forward to working with relocation of our vaccine development laboratories Peter J. Hotez, MD, PhD (TCH), which now host the PDP. The addition of these you to overcome these global challenges in the years to Houston, Texas. In September 2011, our product President, Sabin Vaccine Institute prestigious institutions and their financial support will to come. development laboratories moved to a state-of-the- enable us to significantly expand our capacity to art, 20,000 square foot facility at the Feigin Center develop and deliver vaccines for a range of diseases Sincerely, of Texas Children’s Hospital and Baylor College affecting the poorest people around the globe. of Medicine, located in the renowned Texas Medical In addition, our partnership with these two world- Center (TMC), the world’s largest medical center. renowned institutions provides an important link Morton P. Hyman Michael W. Marine Texas Children’s Hospital and Baylor College of between our research and treatment initiatives and Chairman of the Board Chief Executive Officer Medicine will become major investors in the Sabin the BCM/TCH network of pediatric centers of of Trustees Vaccine Institute PDP. excellence across Africa. 2 Sabin Annual Report 2010 3 THE SABIN Honoring a lifetime of scientific achievement by pioneering new STORY health solutions for the world’s poor. In 1993, the Albert B. Sabin Vaccine Institute was diseases by working with leading health agencies, founded in honor of one of the most influential pharmaceutical companies, and senior government scientists of the 20th century. Over time, Sabin grew officials to expand the demand for and reduce the into a leading advocacy and scientific organization price of these lifesaving vaccines. Ultimately, dedicated to developing lifesaving vaccines and governments must prioritize immunization policies expanding access to existing vaccines and medicines and adopt measures for vaccination programs to be for the poorest people around the world. paid out of their own national budgets. To help meet these sustainability goals, Sabin works with Since its inception, Sabin has placed a premium low-income countries to strengthen and pay for on the value of partnerships for addressing complex immunization programs themselves. global health challenges. Our three main programs —the Sabin Vaccine Institute Product Development As researchers, scientists, and advocates, we Partnership, the Global Network for Neglected Tropical understand that making a positive impact on
Load more

Recommended publications
  • Vaccination with Recombinant Aspartic Hemoglobinase Reduces Parasitic Load and Blood Loss After Hookworm Infection in Dogs
    Open access, freely available online PLoS MEDICINE Vaccination with Recombinant Aspartic Hemoglobinase Reduces Parasite Load and Blood Loss after Hookworm Infection in Dogs Alex Loukas1*, Jeffrey M. Bethony2, Susana Mendez2, Ricardo T. Fujiwara2, Gaddam Narsa Goud2, Najju Ranjit1, Bin Zhan2, Karen Jones2, Maria Elena Bottazzi2, Peter J. Hotez2* 1 Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia, 2 Department of Microbiology and Tropical Medicine, The George Washington University Medical Center, Washington, District of Columbia, United States of America Competing Interests: The authors have declared that no competing ABSTRACT interests exist. Background Author Contributions: AL, JMB, MEB, and PJH designed the study. Hookworms infect 730 million people in developing countries where they are a leading cause AL, RTF, GNG, NR, BZ, performed of intestinal blood loss and iron-deficiency anemia. At the site of attachment to the host, adult experiments. AL, PJH, JMB, SM, and hookworms ingest blood and lyse the erythrocytes to release hemoglobin. The parasites KJ analyzed the data. AL, PJH, JMB, and SM contributed to writing the subsequently digest hemoglobin in their intestines using a cascade of proteolysis that begins paper. with the Ancylostoma caninum aspartic protease 1, APR-1. Academic Editor: Maria Yazdanbakhsh, Leiden University Methods and Findings Medical Center, the Netherlands Citation: Loukas A, Bethony JM, We show that vaccination of dogs with recombinant Ac-APR-1 induced antibody and cellular Mendez S, Fujiwara RT, Goud GN, et responses and resulted in significantly reduced hookworm burdens (p ¼ 0.056) and fecal egg al. (2005) Vaccination with counts (p ¼ 0.018) in vaccinated dogs compared to control dogs after challenge with infective recombinant aspartic hemoglobinase reduces parasite larvae of A.
    [Show full text]
  • TESTIMONY Peter J. Hotez MD, Phd President, Sabin Vaccine Institute
    TESTIMONY Peter J. Hotez MD, PhD President, Sabin Vaccine Institute “The Growing Threat of Cholera and Other Diseases in the Middle East” Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Committee on Foreign Affairs United States House of Representatives March 2, 2016 Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to speak with you today. I am Peter Hotez, a biomedical scientist and pediatrician. I am the dean of the National School of Tropical Medicine at Baylor College of Medicine and also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics based at the Texas Medical Center in Houston. I am also past president of the American Society of Tropical Medicine and Hygiene, and currently serve as President of the Sabin Vaccine Institute, a non-profit which develops vaccines for neglected tropical diseases (NTDs) through a product development partnership (PDP) model. This year I am also serving as US Science Envoy for the State Department and White House Office of Science and Technology Policy focusing on the urgency to develop vaccines for diseases that are emerging in the Middle East and North Africa due to the breakdowns in health systems in the ISIS occupied conflict zones in Syria, Iraq, Libya, and also Yemen. In my submitted written testimony I highlighted some of the successes in US global health policy, many of which can be attributed to the hard work of this Subcommittee working hand in glove with two presidential administrations since 2000. I cite evidence from the Global Burden of Disease Study (GBD) that brings together hundreds of scientists - I am also a part of this - who are measuring the impact of large scale global health programs.
    [Show full text]
  • Pichia Pastoris (Komagataella Phaffii) As a Cost-Effective Tool for Vaccine
    bioengineering Review Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs) Salomé de Sá Magalhães and Eli Keshavarz-Moore * Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK; [email protected] * Correspondence: [email protected] Abstract: Vaccination is of paramount importance to global health. With the advent of the more recent pandemics, the urgency to expand the range has become even more evident. However, the potential limited availability and affordability of vaccines to resource low- and middle-income countries has created a need for solutions that will ensure cost-effective vaccine production methods for these countries. Pichia pastoris (P. pastoris) (also known as Komagataella phaffii) is one of the most promising candidates for expression of heterologous proteins in vaccines development. It combines the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems, potentially reducing manufacturing costs. This review will examine the latest developments in P. pastoris from cell engineering and design to industrial production systems with focus on vaccine development and with reference to specific key case studies. Keywords: vaccines; LMICs; expression platforms; P. pastoris (Komagataella phaffii) Citation: de Sá Magalhães, S.; Keshavarz-Moore, E. Pichia pastoris (Komagataella phaffii) as a Cost-Effective 1. Introduction Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs). Infectious diseases have a significant global economic and societal impact. As a result, Bioengineering 2021, 8, 119. https:// during the last two centuries, we have witnessed the remarkable success of vaccination doi.org/10.3390/bioengineering8090119 reducing the burden of infectious diseases [1].
    [Show full text]
  • The Search for a Schistosomiasis Vaccine: Australia’S Contribution
    Review The Search for a Schistosomiasis Vaccine: Australia’s Contribution Donald P. McManus Molecular Parasitology Laboratory, Infectious Diseases Division, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia; [email protected]; Tel.: +61-418-744-006 Abstract: Schistosomiasis, a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, results in considerable human morbidity in sub-Saharan Africa, in particular, but also parts of the Middle East, South America, and Southeast Asia. The anti-schistosome drug praziquantel is efficacious and safe against the adult parasites of all Schistosoma species infecting humans; however, it does not prevent reinfection and the development of drug resistance is a constant concern. The need to develop an effective vaccine is of great importance if the health of many in the developing world is to be improved. Indeed, vaccination, in combination with other public health measures, can provide an invaluable tool to achieve lasting control, leading to schistosomiasis elimination. Australia has played a leading role in schistosomiasis vaccine research over many years and this review presents an overview of some of the significant contributions made by Australian scientists in this important area. Keywords: Schistosoma; schistosomiasis; vaccine; vaccination; Australia; Australian researchers 1. Introduction Citation: McManus, D.P. The Search for a Schistosomiasis Vaccine: The neglected tropical parasitic disease of schistosomiasis, caused by blood flukes of Australia’s Contribution. Vaccines the genus Schistosoma, has long been a scourge of humankind. It results in considerable 2021, 9, 872. https://doi.org/ morbidity, even leading to death, in sub-Saharan Africa, parts of South America, the Middle 10.3390/vaccines9080872 East and Southeast Asia.
    [Show full text]
  • Pdf SPBA13/6
    13th SESSION OF THE SUBCOMMITTEE ON PROGRAM, BUDGET, AND ADMINISTRATION OF THE EXECUTIVE COMMITTEE Washington, D.C., USA, 27-29 March 2019 Provisional Agenda Item 3.5 SPBA13/6 16 January 2019 Original: English NON-STATE ACTORS IN OFFICIAL RELATIONS WITH PAHO Introduction 1. At the 55th Directing Council, Member States of the Pan American Health Organization (PAHO) adopted the Framework of Engagement with non-State Actors (FENSA) via Resolution CD55.R3 (September 2016). Through this resolution, the PAHO Member States specifically replaced the Principles Governing Relations between the Pan American Health Organization and Nongovernmental Organizations with FENSA. They also requested the Director of the Pan American Sanitary Bureau (“the Bureau”) to implement FENSA in a manner consistent with PAHO’s constitutional legal framework and to report annually to the Executive Committee through its Subcommittee on Program, Budget, and Administration (SPBA). 2. “Official relations” is a privilege that the Executive Committee may grant to nongovernmental organizations, international business associations, and philanthropic foundations that have had, and continue to have, sustained and systematic engagement with PAHO that is assessed by both parties as being mutually beneficial. Entities in official relations with PAHO should be regional in membership and/or scope and should have a constitution or similar basic document, an established headquarters, a governing body, and an administrative structure. 3. Official relations are based on a three-year plan for collaboration with PAHO that has been developed and agreed on jointly by the non-State actor and PAHO. The three-year plan is structured in accordance with the PAHO Strategic Plan and cannot be primarily of a commercial or for-profit nature.
    [Show full text]
  • 1999 Annual Report
    1999 1999 BANBURY CENTER DIRECTOR'S REPORT The Banbury Center program continues to be as eclectic and exciting as ever. The year was filled with more meetings than ever before-a record 23 of them! Laboratory scientists used the Center for seven in-house meetings, and local community groups came here on eight occasions. Together with the five neurobiology courses, there was hardly a week when the Center was not in use. Not surprisingly, 1999 was also a record year for the number of visitors to Banbury Center: 667 par­ ticipants attended the 23 meetings. The demographics of our participants remain much the same: 25% of visitors to Banbury Center came from abroad, with the United Kingdom, Germany, and Canada lead­ ing the way. Of the American scientists, those from New York, Massachusetts, and California together accounted for more than 32% of the total. However, participants were drawn from no fewer than 42 states. This is the first year that we have been able to use the Meier House to accommodate participants, which proved to be wonderful. Now the number of participants that we can house on the Banbury estate matches the number we can have in the Conference Room-we do not have to transport peo­ ple between the Center and the main campus. Biological and biomedical research is becoming ever more interdisciplinary, and as it does so, it also becomes ever more difficult to categorize the topics of Banbury Center meetings. A meeting may deal with the same phenomenon in a range of organisms, or many different strategies may be used to study one phenomenon in a single species.
    [Show full text]
  • Sabin in the News Recent Scientific Articles Sabin Vaccine Institute
    Home About Us News & Resources Support Sabin Sabin in the News October 2011 The Sabin Report | Volume 13 Issue 2 New York Times article featuring Dr. Peter Hotez's new study on increased Sabin Vaccine Institute Establishes a Houston prevalence of NTDs in Europe. Office Drs. Ciro de Quadros and In September 2011, the Zulfiqar Bhutta highlight Sabin Vaccine Institute the dire need for a dengue established offices in vaccine in an opinion Houston, Texas in the piece for GlobalPost. heart of the city's Texas Medical Center (TMC). The In an interview on Voice of new facilities will house the America Dr. Peter Hotez Sabin Vaccine Institute & focused on NTDs in Sub- Texas Children's Hospital Saharan Africa. Center for Vaccine Development, which will be An article by Dr. Neeraj operated in partnership Mistry was featured in a with Baylor College of special supplemental Medicine Department of section of the USA today, Pediatrics. Sabin Dr. Hotez and team at Sabin's new Houston facility titled "Neglected Diseases President, Dr. Peter J. in Developing Nations". Hotez will direct the new center. In an op-ed for the Houston Chronicle, Dr. The new space includes offices and laboratories through which the Peter Hotez writes about Sabin Vaccine Institute Product Development Partnership (PDP) will the establishment of the advance and strengthen its collaborative work in the field of vaccine new School of Tropical biotechnology. The change is the result of a year-long plan to expand Medicine at Baylor College the scope and depth of the Sabin PDP's partnership and to enhance of Medicine.
    [Show full text]
  • Artículos Científicos
    Editor: NOEL GONZÁLEZ GOTERA Número 086 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 010613 - 070613 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS Publicaciones incluidas en PubMED durante el período comprendido entre el el 1 y el 7 de junio de 2013. Con “vaccin*” en título: 131 artículos recuperados. Vacunas Neumococo (Streptococcus pneumoniae) 98. Is there an authentic increased risk of pneumococcal pneumonia among young mothers whose children were fully vaccinated with PCV7? The role of methodological shortcomings. Castiglia P, Piana A, Sotgiu G. Vaccine. 2013 May 29. doi:pii: S0264-410X(13)00655-5. 10.1016/j.vaccine.2013.05.055. [Epub ahead of print] No abstract available. PMID: 23727001 [PubMed - as supplied by publisher] Related citations Select item 23726847 121. Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine. Loman NJ, Gladstone RA, Constantinidou C, Tocheva AS, Jefferies JM, Faust SN, O'Connor L, Chan J, Pallen MJ, Clarke SC. PLoS One. 2013 May 28;8(5):e64731. doi: 10.1371/journal.pone.0064731. Print 2013. PMID: 23724086 [PubMed - in process] Free Article Related citations Select item 23724021 1 Vacuna Tosferina (Bordetella pertussis) 108. [Pertussis in fully vaccinated infants and children. Are new vaccination strategies required?] Moraga-Llop FA, Mendoza-Palomar N, Muntaner-Alonso A, Codina-Grau G, Fàbregas-Martori A, Campins-Martí M. Enferm Infecc Microbiol Clin. 2013 May 29. doi:pii: S0213-005X(13)00124-9. 10.1016/j.eimc.2013.04.007. [Epub ahead of print] Spanish. PMID: 23725786 [PubMed - as supplied by publisher] Related citations Select item 23725785 125.
    [Show full text]
  • Environmental Characteristics Around the Household and Their Association with Hookworm Infection in Rural Communities from Bahir Dar, Amhara Region, Ethiopia
    RESEARCH ARTICLE Environmental characteristics around the household and their association with hookworm infection in rural communities from Bahir Dar, Amhara Region, Ethiopia Melaku Anegagrie1,2☯, SofõÂa Lanfri3,4☯, Aranzazu Amor Aramendia1,2, Carlos 3,5 2 2 4 MatõÂas ScavuzzoID , Zaida HerradorID , AgustõÂn BenitoID , Maria Victoria PeriagoID * 1 FundacioÂn Mundo Sano, Madrid, Spain, 2 National Centre for Tropical Medicine, Institute of Health Carlos III, Madrid, Spain, 3 Instituto de Altos Estudios Espaciales Mario Gulich, ComisioÂn Nacional de Actividades Espaciales, Universidad Nacional de CoÂrdoba, CoÂrdoba, Argentina, 4 FundacioÂn Mundo Sano, Buenos a1111111111 Aires, Argentina, 5 Consejo Nacional de Investigaciones CientõÂficas y TeÂcnicas (CONICET), Buenos Aires, a1111111111 Argentina a1111111111 ☯ These authors contributed equally to this work. a1111111111 * [email protected] a1111111111 Abstract OPEN ACCESS Soil-Transmitted Helminths (STH) are highly prevalent Neglected Tropical Disease in Ethio- pia, an estimated 26 million are infected. Geographic Information Systems and Remote Citation: Anegagrie M, Lanfri S, Aramendia AA, Scavuzzo CM, Herrador Z, Benito A, et al. (2021) Sensing (RS) technologies assist data mapping and analysis, and the prediction of the spa- Environmental characteristics around the tial distribution of infection in relation to environmental variables. The influence of socioeco- household and their association with hookworm nomic, environmental and soil characteristics on hookworm infection at the individual and infection in rural communities from Bahir Dar, household level is explored in order to identify spatial patterns of infection in rural villages Amhara Region, Ethiopia. PLoS Negl Trop Dis 15(6): e0009466. https://doi.org/10.1371/journal. from Zenzelema (Amhara region). Inhabitants greater than 5 years old were recruited in pntd.0009466 order to assess the presence of STH.
    [Show full text]
  • The Neglected Tropical Diseases: the Ancient Afflictions of Stigma And
    3 The Neglected Tropical Diseases: The Ancient Affl ictions of Stigma and Poverty and the Prospects for their Control and Elimination Peter Hotez, Eric Ottesen, Alan Fenwick, and David Molyneux 1. Introduction The World Health Organizations and other international health agencies iden- tify a select group of 13 tropical infections as the neglected tropical diseases (NTDs). These diseases, which include leprosy, kala-azar, river blindness, guinea worm, schistosomiasis, hookworm and lymphatic fi lariasis, strike the world’s poorest people living in remote and rural areas of low-income countries in Sub-Saharan Africa, Asia and the Americas. They infl ict suffering by causing life-long disabili- ties, disfi gurement, reduced economic productivity, and social stigma (WHO, 2003). Unlike better-known global health threats such as HIV-AIDS, malaria, and tuber- culosis, the NTDs do not receive enough international attention. Instead, they are neglected diseases among forgotten people found only in the setting of geographic isolation and intense poverty (Molyneux, 2004). Impoverished and marginalized populations with the NTDs represent the lowest priority markets for U.S. and European pharmaceutical manufacturers. The NTDs do not occur in the industrialized world or even among the substantial wealthy and middle-classes in developing countries. They are not a signifi cant health risk for foreign travelers or the military. This is in contrast to the more substantial com- mercial markets for HIV-AIDS, malaria and tuberculosis (“the big three”). The recent creation of massive funding schemes for the big three, such as The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the U.S.
    [Show full text]
  • Spatial Distribution of Phlebotominae in Puerto Iguazú-Misiones, Argentina-Brazil- Paraguay Border Area
    Rev. Inst. Med. Trop. Sao Paulo 55(4):1-xxx, July-August, 2013 doi: 10.1590/S0036-466520130004000?? SPATIAL DISTRIBUTION OF PHLEBOTOMINAE IN PUERTO IGUAZÚ-MISIONES, ARGENTINA-BRAZIL- PARAGUAY BORDER AREA María Soledad SANTINI(1,4), Ignacio Tomas GOULD(1,4), Mariana Manteca ACOSTA(2,4), Pablo BERROZPE(1,4), Soraya Alejandra ACARDI(3,4,6), María Soledad FERNÁNDEZ(1,4,6), Andrea GÓMEZ(5) & Oscar Daniel SALOMON(2,4,6) SUMMARY The first Argentinian autochthonous human case of visceral leishmaniasis (VL) was confirmed in Posadas (Misiones) in 2006. Since then, the disease has increased its incidence and geographical distribution. In the 2006-2012 period, 107 human cases were detected (11 deaths). The presence of Lutzomyia longipalpis was detected in peridomiciles in Puerto Iguazú urban area in 2010; some of these findings were associated with households where cases of canine VL had already been reported. The objective of this study was to ascertain the abundance and spatial distribution of Lu. longipalpis in Puerto Iguazú City, on the Argentina-Brazil-Paraguay border. Lu. longipalpis proved to be exclusively urban and was found in 31% of the households sampled (n = 53), 67% of which belonged to areas of low abundance, 20% to areas of moderate abundance and 13% to areas of high abundance. Nyssomyia whitmani was the only species found both in urban and peri-urban environments, and Migonemyia migonei was registered only on the outskirts of the city. Due to the fact that Puerto Iguazú is considered to be at moderate risk at the moment, it is necessary to intensify human and canine case controls, as well as take integrated prevention and control measures regarding the environment, vectors and reservoirs on the Argentina-Brazil-Paraguay border area.
    [Show full text]
  • The GAVI Alliance
    GLOBAL PROGRAM REVIEW The GAVI Alliance Global Program Review The World Bank’s Partnership with the GAVI Alliance Main Report and Annexes Contents ABBREVIATIONS .................................................................................................................................. V ACKNOWLEDGMENTS ........................................................................................................................ XI PROGRAM AT A GLANCE: THE GAVI ALLIANCE ............................................................................ XII KEY BANK STAFF RESPONSIBLE DURING PERIOD UNDER REVIEW ........................................ XIV GLOSSARY ......................................................................................................................................... XV OVERVIEW ........................................................................................................................................ XVII GAVI ALLIANCE MANAGEMENT RESPONSE .............................................................................. XXV WORLD BANK GROUP MANAGEMENT RESPONSE ................................................................... XXIX CHAIRPERSON’S SUMMARY ......................................................................................................... XXXI 1. THE WORLD BANK-GAVI PARTNERSHIP AND THE PURPOSE OF THE REVIEW ...................... 1 Evolution of GAVI .....................................................................................................................................................
    [Show full text]